Novartis unit Sandoz sues to revoke Bayer’s patents for blood thinner Xarelto
Intellectual Property 2021-11-23 3:30 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au